Fundraising FoxVI Partners — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.
BiotechDeep TechHealthtechMedical Devices
Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in
Co-investorsInkef3B Future Health FundM VenturesXGEN VentureJohnson & Johnson Innovation – JJDC
Somagenetix is a gene therapy company that develops treatments for genetic diseases, particularly phagocyte-driven immune and neurodegenerative disorders, by correcting DNA at its source.
BiotechDeep TechHealthtechMedical DevicesZurich, CH
Co-investorsVerve Ventures
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.